Drugs / VRB-103
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07628127 | Jul 2026 → Mar 2028 expected | obesity disorder | Verdiva Bio Dev Limited | Not yet recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2026-06-05 | Verdiva Bio Dev Limited | Results Verdiva Bio Presents Preclinical Data on Investigational Obesity Drug Candidates at the American Diabetes Association 86th Scientific Sessions verdivabio.com ↗ |
| 2025-06-21 | Verdiva Bio Dev Limited | Results Verdiva Bio to present new data highlighting once-weekly potential of its investigational oral obesity candidates at the ADA 85th Scientific Sessions verdivabio.com ↗
Preclinical data on VRB-103, Verdiva Bio’s once-weekly, oral amylin analog, supports continued development, both as a monotherapy and as a single tablet co-formulation with VRB-101. |
All press releases naming this drug 4 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-09-29 | Verdiva Bio Dev Limited | Verdiva Bio Presents Preclinical Data on VRB-103, a Selective Oral Amylin Peptide Analog, at 62nd EASD Annual Meeting verdivabio.com ↗ |
| 2026-07-30 | Verdiva Bio Dev Limited | Verdiva Bio Initiates Phase 1 Study of VRB-103, a Selective Oral Amylin Peptide Analog with Weekly Dosing Potential verdivabio.com ↗ |
| 2026-06-05 | Verdiva Bio Dev Limited | Verdiva Bio Presents Preclinical Data on Investigational Obesity Drug Candidates at the American Diabetes Association 86th Scientific Sessions verdivabio.com ↗ |
| 2025-06-21 | Verdiva Bio Dev Limited | Verdiva Bio to present new data highlighting once-weekly potential of its investigational oral obesity candidates at the ADA 85th Scientific Sessions verdivabio.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VRB-103 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07628127 ↗ |
| Route | Oral | “administered orally” NCT07628127 ↗ |